Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CKD-381 vs D026 in Healthy Males
NCT03444402Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Mar 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-381 in gastroesophageal reflux disease (GERD) (3 arms), sponsored by Chong Kun Dang Holdings. Primary endpoint: Area under the plasma drug concentration-time curve within a dosing interval at steady state. Started Mar 2018; status: completed.
02
Drugs
CKD-381
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT03444402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03444402.